PATENT CLAIM ANALYSIS

Application Number: 15750151
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "043000"]

Abstract:
Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.

Claim (Index 14):
The method of  claim 13 , wherein the hematological cancer is acute myelogenous leukemia (AML).

Metadata:
- Claim Count in Document: 104.0
- Percentile: 88.0
- Lexical Diversity: 1.19231
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15673213', '15112768', '12310575', '15278550', '14103359']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6792695446358712
- 35 USC 102 Novelty (BERT): 0.4880853407267358
- Combined Prediction Score: 0.6601511242449577
- Mean Citation Score: 199.30272
- Max Citation Score: 212.29048
- Similarity Product: 173.61883212010383

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test